DOI: https://doi.org/10.24061/2413-4260.IV.3.13.2014.17

ГРИБКОВІ ІНФЕКЦІЇ В НЕОНАТОЛОГІЇ – СУЧАСНИЙ ПОГЛЯД НА ПРОБЛЕМУ

T. Znamenska, T. Kurilina

Анотація


Представлено сучасні погляди на питання діагностики, лікування і профілактики мікозів у новонароджених, які пропонується покласти у основу клінічної настанови.

Ключові слова


новонароджені; грибкові інфекції; кандидоз; аспергильоз; діагностика; лікування; профілактика

Повний текст:

PDF

Посилання


.1 Klimko NN. Diagnostika i lechenie opportunisticheskikh mikozov [Diagnosis and treatment of opportunistic mycoses]. Peterburg, 2008. 196s. (in Russian).

.2 Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed. 2001;84(2):F131-3. doi: 10.1136/fn.84.2.f131

.3 Austin N, Darlow BA, McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev. 2013;(3):CD003478. doi: 10.1002/14651858.CD003478

.4 Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2013;(4):CD003850. doi: 10.1002/14651858.

.5 Aydemir C, Oguz SS, Dizdar EA, Akar M, Sarikabadayi YU, Saygan S, et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 2011;96(3):F164-8. doi: 10.1136/adc.2009.178996

.6 Baley JE, Ellis FJ. Neonatal candidiasis: ophthalmologic infection. Semin Perinatol. 2003;27(5):401-5. doi: 10.1016/s0146-0005(03)00064-8

.7 Infectious diseases of the Fetus and Newborn Infant. Remington JS (Ed.). Elsevier Saunders, Philadelphia, PA, USA, 2010. Bendel CM. Candidiasis. 1055p.

.8 Benjamin DK Jr, Stoll BJ, Gantz MG, Walsh MC, Sánchez PJ, Das A, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126(4):e865-73. doi: 10.1542/peds.2009-3412

.9 Clerihew L, McGuire W. Antifungal therapy for newborn infants with invasive fungal infection. Cochrane Database Syst Rev. 2012;(6):CD003953. doi: 10.1002/14651858.

.10 Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-97.

.11 Ullmann AJ, Cornely OA, Donnelly JP, Akova M, Arendrup MC, Arikan-Akdagli S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect. 2012;18(7):1-8. doi: 10.1111/1469-0691.12037.

.12 De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21. doi: 10.1086/588660.

.13 Errol R. Fundamental medical mycology: Wiley-Blackwell, 2012. 630p.

.14 Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-15.

.15 Heresi GP, Gerstmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25(12):1110-5.

.16 Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18(7):38-52. doi: 10.1111/1469-0691.12040.

.17 Hsieh E, Smith PB, Jacqz-Aigrain E, Kaguelidou F, Cohen-Wolkowiez M, Manzoni P, et al. Neonatal fungal infections: when to treat? Early Hum Dev. 2012;88(2):S6-S10. doi: 10.1016/S0378-3782(12)70004-X.

.18 Karlowicz MG. Candidal renal and urinary tract infection in neonates. Semin Perinatol. 2003;27(5):393-400. doi: 10.1016/s0146-0005(03)00063-6

.19 Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin. 2010;26(7):1769-78. doi: 10.1185/03007995.2010.487799.

.20 Kirby A, Hassan I, Burnie J. Recommendations for managing Aspergillus osteomyelitis and joint infections based on a review of the literature. J Infect. 2006;52(6):405-14. doi: 10.1016/j.jinf.2005.08.016

.21 Linder N, Klinger G, Shalit I, Levy I, Ashkenazi S, Haski G, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003;52(4):663-7.

.22 Manzoni P, Benjamin DK, Hope W, Rizzollo S, Del Sordo P, Stronati M, et al. The management of Candida infections in preterm neonates and the role of micafungin. J Matern Fetal Neonatal Med. 2011;24(2):24-7. doi: 10.3109/14767058.2011.604929.

.23 Manzoni P, Stolfi I, Pugni L, Decembrino L, Magnani C, Vetrano G, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356(24):2483-95. doi: 10.1056/NEJMoa065733

.24 Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics. 2012;129(1):116-23. doi: 10.1542/peds.2011-0279.

.25 Manzoni P, Mostert M, Leonessa ML, Priolo C, Farina D, Monetti C, et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis. 2006;42(12):1735-42. doi: 10.1086/504324

.26 Martini A, Gottin L, Menestrina N, Schweiger V, Simion D, Vincent JL. Procalcitonin levels in surgical patients at risk of candidemia. J Infect. 2010;60(6):425-30. doi: 10.1016/j.jinf.2010.03.003.

.27 Mikulska M, Viscoli C. Current role of echinocandins in the management of invasive aspergillosis. Curr Infect Dis Rep. 2011;13(6):517-27. doi: 10.1007/s11908-011-0216-6.

. 28 Montagna MT, Coretti C, Lovero G, De Giglio O, Montagna O, Laforgia N, et al. Diagnostic Performance of 1,3-beta-D-Glucan in Neonatal and Paediatric Patients with Candidemia. Int J Mol Sci. 2011; 12(9): 5871–7. doi: 10.3390/ijms12095871

.29 Montagna MT, Coretti C, Caggiano G. Procalcitonin: a possible marker of invasive fungal infection in high risk patients? J Prev Med Hyg. 2011;52(1):38-9.

.30 Pappas PG, Kauffman C, Andes D, Benjamin DK, CalandraTF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-35.

.31 Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore). 2000;79(4):250-60.

.32 Pickering LK, Baker CJ, Kimberlin DW, Long SS, editor. 2012 Report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village, IL, USA, 2012. Pickering LK, Pediatrics AAР. Candidiasis. P.265-9.

.33 Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J. 2011;30(5):375-8. doi: 10.1097/INF.0b013e318202cbb3.

.34 Richardson MD, Warnock DW, editor. Fungal infection: diagnosis and management - 4thed. Blackwell Publishing Ltd, 2012. 445p.

.35 Richardson MD, Jones BL. Therapeutic Guidelines in Systemic Fungal Infections.4thed. Current Medical Literature, 2007. 126p.

.36 Thakre Rh. Systemic fungal infections – emerging infection in newborn. Journal of Neonatology. 2011;25(2):69-72.

.37 Ullmann AJ, Cornely OA, Donnelly JP, Akova M, Arendrup MC, Arikan-Akdagli S, et al. ESCMID: Diagnostic and Management Guideline for Candida Diseases 2012: Developing European Guidelines in Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2012;18(7):1-8. doi: 10.1111/1469-0691.12037.

.38 Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-60. doi: 10.1086/525258.

.39 Young TE, Mangum B. Neofax: A Manual of drugs used in neonatal care, 26th ed. Raleigh, North Carolina: Acorn Publishing, USA, 2013. 334p.

.40 Zaoutis T. Candidemiain children. Curr Med Res Opin. 2010;26(7):1761-8. doi: 10.1185/03007995.2010.487796.




Copyright (c) 2019 T. Znamenska, T. Kurilina

Creative Commons License
Ця робота ліцензована Creative Commons Attribution 4.0 International License.

Creative Commons License
Журнал «Неонатологія, хірургія та перинатальна медицина» ISSN 2413-4260 (Online), ISSN 2226-1230 (Print) This work is licensed under a Creative Commons Attribution 4.0 International License.